Myocardial gene therapy.
Gene therapy is proving likely to be a viable alternative to conventional therapies in coronary artery disease and heart failure. Phase 1 clinical trials indicate high levels of safety and clinical benefits with gene therapy using angiogenic growth factors in myocardial ischaemia. Although gene therapy for heart failure is still at the pre-clinical stage, experimental data indicate that therapeutic angiogenesis using short-term gene expression may elicit functional improvement in affected individuals.
Isner
Jeffrey M
JM
Department of Medicne, St. Elizabeth's Medical Center, Tufts School of Medicine, Boston, MA 02135, USA.
D000818:Animals; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000235:genetics / Q000628:therapy; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006333:Heart Failure / Q000235:genetics / Q000628:therapy*; D006801:Humans; D017202:Myocardial Ischemia / Q000628:therapy*